Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

First International Summit on Interventional Pharmacoeconomics

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Opening Session Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Cost of Care

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Apr

Today In Oncology

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Opening Session Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin

FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL

AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation

Prompting Strategies Improve Symptom Monitoring in Childhood Cancer Survivors

Patients With Lung Cancer May Safely Receive Adequate SBRT Dosage in One Treatment